Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability.
Ardelyx: Low Price, But High Implied Valuation
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside.
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
Ardelyx (ARDX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability
Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidance for $410–$430M 2026 revenue and a $1B annual target by 2029, supported by patent protection through 2042. Xphozah revenue is declining and maturing, while heavy operational spend and net losses raise concerns about cost discipline and sustainability.
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx (ARDX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ardelyx (ARDX) Reports Break-Even Earnings for Q4
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
